Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRME Prime Medicine, Inc.

Closed 07-09 16:00:00 EDT

4.23

-0.39

-8.44%

盘后4.23

+0.000.00%

19:58 EDT

High4.73	Low4.17	Vol4.87M
Open4.58	D1 Closing4.62	Amplitude12.12%
Mkt Cap763.56M	Tradable Cap486.45M	Total Shares180.51M
T/O21.44M	T/O Rate4.23%	Tradable Shares115.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRME","market":"US","secType":"STK","nameCN":"Prime Medicine, Inc.","latestPrice":4.23,"timestamp":1783627200000,"preClose":4.62,"halted":0,"volume":4868531,"hourTrading":{"tag":"盘后","latestPrice":4.23,"preClose":4.23,"latestTime":"19:58 EDT","volume":35851,"amount":152486.7665,"timestamp":1783641534493,"change":0,"changeRate":0,"amplitude":0.023641},"delay":0,"changeRate":-0.08441558441558435,"floatShares":114999999,"shares":180510658,"eps":-1.237435,"marketStatus":"Closed","change":-0.39,"latestTime":"07-09 16:00:00 EDT","open":4.58,"high":4.73,"low":4.17,"amount":21435918.040574,"amplitude":0.121212,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.237435,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783670400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1666238400000,"exchange":"NASDAQ","adjPreClose":4.62,"preHourTrading":{"tag":"盘前","latestPrice":4.56,"preClose":4.62,"latestTime":"09:29 EDT","volume":16032,"amount":74742.95233,"timestamp":1783603789868,"change":-0.06,"changeRate":-0.012987,"amplitude":0.063528},"postHourTrading":{"tag":"盘后","latestPrice":4.23,"preClose":4.23,"latestTime":"19:58 EDT","volume":35851,"amount":152486.7665,"timestamp":1783641534493,"change":0,"changeRate":0,"amplitude":0.023641},"volumeRatio":0.827669,"impliedVol":0.9995,"impliedVolPercentile":0.2988},"requestUrl":"/m/hq/s/PRME","defaultTab":"news","newsList":[{"id":"2650693990","title":"TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647","url":"https://stock-news.laohu8.com/highlight/detail?id=2650693990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650693990?lang=en_us&edition=fundamental","pubTime":"2026-07-09 00:45","pubTimestamp":1783529110,"startTime":"0","endTime":"0","summary":"TD Cowen notes that Prime Medicine (PRME) announced a positive binding arbitration resolution with Beam Therapeutics (BEAM) over PM647 in alpha-1 a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/td-cowen-says-arbitration-decision-removes-overhang-for-prime-medicines-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/td-cowen-says-arbitration-decision-removes-overhang-for-prime-medicines-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","BK4505","BK4207","BK4585","PRME","BEAM","LU1861558580.USD","BK4127","GSIB","BK4588","BK4556","LU1861559042.SGD","TD","BK4139","BK4535","COWN","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650997531","title":"Resolution in favor of Prime has limited impact to Beam, says BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2650997531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650997531?lang=en_us&edition=fundamental","pubTime":"2026-07-08 23:45","pubTimestamp":1783525515,"startTime":"0","endTime":"0","summary":"BofA analyst Alec Stranahan reiterated a Buy rating and $47 price target on Beam Therapeutics (BEAM) after Prime Medicine (PRME) announced a “posit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/resolution-in-favor-of-prime-has-limited-impact-to-beam-says-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/resolution-in-favor-of-prime-has-limited-impact-to-beam-says-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4556","BK4535","BEAM","BK4585","PRME","BK4611","LU1861558580.USD","BK4139","LU1861559042.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649923159","title":"Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649923159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649923159?lang=en_us&edition=fundamental","pubTime":"2026-07-08 23:00","pubTimestamp":1783522811,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Resmed (RMD) and Prime Medicine, Inc. (PRME). Resm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-resmed-rmd-and-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-resmed-rmd-and-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RMD","LGHT","BK4137","PRME","IE00B5TLWC47.USD","BK4504","XBI","LABU","BK4585","BK4082","BK4588","BK4581","BK4139","XLV","LU0029874061.USD","HCSG","BK4548","LU0128526141.USD","BK4567","LU2008162690.USD","LU2177674079.SGD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649951329","title":"Prime Medicine Posts Corporate Deck Highlighting Prime-editing Platform, Lead Programs in Wilson Disease and AATD","url":"https://stock-news.laohu8.com/highlight/detail?id=2649951329","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649951329?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:22","pubTimestamp":1783513324,"startTime":"0","endTime":"0","summary":"Prime Medicine posts corporate deck highlighting prime-editing platform, lead programs in Wilson disease and AATDPrime Medicine set near-term priorities on in vivo liver programs for Wilson disease an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL8X0NNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649853995","title":"Prime Medicine Wins Arbitration with Beam over AATD Therapy PM647","url":"https://stock-news.laohu8.com/highlight/detail?id=2649853995","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649853995?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:04","pubTimestamp":1783512297,"startTime":"0","endTime":"0","summary":"Prime Medicine wins arbitration with Beam over AATD therapy PM647Prime Medicine won a binding arbitration with Beam Therapeutics under their 2019 collaboration and license agreement.The tribunal ruled","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL3ghvpw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","SG9999014021.USD","IE00BKPKM429.USD","LU2210150020.SGD","PRME","SG9999014013.SGD","LU2210149790.SGD","BCDF","IE00BGHQF748.EUR","SG9999014039.USD","BK4505","BK4585","IE00BN0W2W23.USD","BK4535","NDAQ","LU1861559042.SGD","IE00BN0W2T93.GBP","BK4556","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD","BEAM","BK4611","BK4112","LU1861558580.USD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649993763","title":"Prime Medicine, - Initial Clinical Data for Pm647 Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2649993763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649993763?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:00","pubTimestamp":1783512008,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUA1PRVQQ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649993757","title":"Prime Medicine, - Arbitration Tribunal Confirms Prime Medicine's Right to Develop and Commercialize Pm647 in Aatd","url":"https://stock-news.laohu8.com/highlight/detail?id=2649993757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649993757?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:00","pubTimestamp":1783512008,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUA1PRVQQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649937669","title":"Prime Medicine, - Owes no Monetary Damages to Beam Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2649937669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649937669?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:00","pubTimestamp":1783512008,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUA1PRVQQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649932909","title":"Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2649932909","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649932909?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:00","pubTimestamp":1783512008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUA1PRVQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649799993","title":"Prime Medicine, - to Submit Ind And/or Cta for Pm647 in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649799993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649799993?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:00","pubTimestamp":1783512008,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUA1PRVQQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649955785","title":"Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine today","url":"https://stock-news.laohu8.com/highlight/detail?id=2649955785","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649955785?lang=en_us&edition=fundamental","pubTime":"2026-07-08 08:15","pubTimestamp":1783469714,"startTime":"0","endTime":"0","summary":"20:12 EDT Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine (PRME) today Published first on TheFly – the ultimate source for real-t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-206-2k-shares-of-prime-medicine-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-206-2k-shares-of-prime-medicine-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKQ","BK4139","SARK","ARKW","ARKF","BK4544","ARKK","BK4588","PRME","ARKX","ARKG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648169670","title":"CYTK, PRME, DOCS, WBD, LQDA Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2648169670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648169670?lang=en_us&edition=fundamental","pubTime":"2026-07-04 17:01","pubTimestamp":1783155676,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($CYTK) ), ( ($PRME) ), ( ($DOCS) ), ( ($WBD) ) and ( ($LQDA) ). Here is a breakdown of their recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/cytk-prme-docs-wbd-lqda-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/cytk-prme-docs-wbd-lqda-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","LQDA","WBD","BK4108","LU0477156953.USD","BK4505","LU0130517989.USD","LU0648001328.SGD","LU1201861249.SGD","BK4007","LU0980610538.SGD","CYTK","BK4139","LU0149725797.USD","BK4125","BK4539","PRME","DOCS","LU0130102774.USD","BK4613","BK4598","BK4585","BK4588","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647137640","title":"HC Wainwright Upgrades Prime Medicine to Buy From Neutral, $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2647137640","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647137640?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:35","pubTimestamp":1782732932,"startTime":"0","endTime":"0","summary":"HC Wainwright Upgrades Prime Medicine to Buy From Neutral, $8 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647337335","title":"Prime Medicine Raised to Buy from Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2647337335","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647337335?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:23","pubTimestamp":1782728580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 06:23 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859683","title":"Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859683","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859683?lang=en_us&edition=fundamental","pubTime":"2026-06-24 03:45","pubTimestamp":1782243915,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on Prime Medicine, Inc. yesterday and set a price target of $8.00. In addition to Wedbush, Prime Medicine, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-prime-medicine-inc-prme-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-prime-medicine-inc-prme-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645800708","title":"Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645800708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645800708?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:30","pubTimestamp":1782210611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PROCEPT BioRobotics (PRCT), Prime Medicine, Inc. (PR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-procept-biorobotics-prct-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-procept-biorobotics-prct-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LABU","LU0029874061.USD","PRME","BK4139","BK4585","LU2324357040.USD","PRCT","HCSG","LU0128526141.USD","XLV","BK4581","BK4588","XBI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645245920","title":"Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Pm359 for the Treatment of Chronic Granulomatous Disease (Cgd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645245920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645245920?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA21NW5G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645018081","title":"Prime Medicine, Inc. (PRME) Receives a Hold from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2645018081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645018081?lang=en_us&edition=fundamental","pubTime":"2026-06-22 00:35","pubTimestamp":1782059741,"startTime":"0","endTime":"0","summary":"In a report released on June 18, Terence Flynn from Morgan Stanley maintained a Hold rating on Prime Medicine, Inc.. The company’s shares closed la...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/prime-medicine-inc-prme-receives-a-hold-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/prime-medicine-inc-prme-receives-a-hold-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0390134368.USD","LU0912757837.SGD","LU0267386448.USD","LU1732800096.USD","LU0795875086.SGD","LU0106831901.USD","LU1720051017.SGD","BK4581","IE00BZ1G4Q59.USD","LU2023251221.USD","LU1988902786.USD","LU1064131342.USD","LU0882574139.USD","BK4588","IE00BKVL7J92.USD","LU0528227936.USD","LU0971096721.USD","LU1074936037.SGD","LU0098860793.USD","LU1363072403.SGD","LU2264538146.SGD","LU2089283258.USD","LU0320765646.SGD","LU1244550577.SGD","LU2028103732.USD","LU1548497426.USD","LU1720051108.HKD","LU0158827948.USD","LU2487616109.SGD","LU0795875169.SGD","LU1162221912.USD","LU1791710400.SGD","BK4127","LU0557290698.USD","LU2133065610.SGD","LU0210528500.USD","LU1668664300.SGD","LU0158827781.USD","PRME","LU2089284900.SGD","BK4534","LU0006306889.USD","LU0225283273.USD","LU0234570918.USD","LU2111349929.HKD","BK4139","LU1244550494.USD","LU2357305700.SGD","LU0053666078.USD","LU2271345857.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644571083","title":"Prime Medicine says New Zealand clears clinical trial application for Wilson disease therapy PM577a","url":"https://stock-news.laohu8.com/highlight/detail?id=2644571083","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644571083?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:03","pubTimestamp":1781784216,"startTime":"0","endTime":"0","summary":"Prime Medicine secured New Zealand Medsafe clearance for a clinical trial application for PM577a in H1069Q-mutated Wilson disease.The authorization enables a global, open-label Phase 1/2 first-in-human study; trial start is expected in 2H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL41r77Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644108339","title":"Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for Pm577a in H1069q-Mutated Wilson Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2644108339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644108339?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:00","pubTimestamp":1781784002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUAB2MBLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.primemedicine.com;investors.primemedicine.com","stockEarnings":[{"period":"1week","weight":0.1877},{"period":"1month","weight":0.5608},{"period":"3month","weight":0.3162},{"period":"6month","weight":0.1726},{"period":"1year","weight":0.1268},{"period":"ytd","weight":0.3314}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0084},{"period":"3month","weight":0.0963},{"period":"6month","weight":0.074},{"period":"1year","weight":0.2016},{"period":"ytd","weight":0.0931}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070058},{"month":2,"riseRate":0.5,"avgChangeRate":0.101559},{"month":3,"riseRate":0,"avgChangeRate":-0.224329},{"month":4,"riseRate":0.5,"avgChangeRate":-0.072402},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000767},{"month":6,"riseRate":0.75,"avgChangeRate":0.248413},{"month":7,"riseRate":1,"avgChangeRate":0.221578},{"month":8,"riseRate":0,"avgChangeRate":-0.164067},{"month":9,"riseRate":0.333333,"avgChangeRate":0.111542},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.141809},{"month":11,"riseRate":0.25,"avgChangeRate":-0.086687},{"month":12,"riseRate":0.5,"avgChangeRate":0.02429}],"exchange":"NASDAQ","name":"Prime Medicine, Inc.","nameEN":"Prime Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Prime Medicine, Inc.,PRME,Prime Medicine, Inc.股票,Prime Medicine, Inc.股票老虎,Prime Medicine, Inc.股票老虎国际,Prime Medicine, Inc.行情,Prime Medicine, Inc.股票行情,Prime Medicine, Inc.股价,Prime Medicine, Inc.股市,Prime Medicine, Inc.股票价格,Prime Medicine, Inc.股票交易,Prime Medicine, Inc.股票购买,Prime Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}